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Abstract
Ubiquitination (a.k.a. ubiquitylation) is a protein post-translational modification that typically requires the
sequential action of three enzymes: E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and
E3 (ubiquitin ligases) [16]. Ubiquitination of proteins can target them for proteasomal degradation, or modulate
cellular processes including cell cycle progression, transcriptional regulation, DNA repair and signal
transduction.
E3 ubiquitin ligases, of which there are >600 in humans, are a family of highly heterogeneous proteins and
protein complexes that recruit ubiquitin-loaded E2 enzymes to mediate transfer of the ubiquitin molecule from
the E2 to protein substrates. Target substrate specificity is determined by a substrate recognition subunit within
the E3 complex.
Contents
This is a citation summary for E3 ubiquitin ligase components in the Guide to Pharmacology database (GtoPdb).
It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by
citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are
given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb
curators.
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E3 ubiquitin ligase components
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1023
    Enzymes
            cereblon
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3086
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